Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
271 studies found for:    NR2E3
Show Display Options
Rank Status Study
1 Completed A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome
Condition: Coronary Heart Disease
Interventions: Drug: dalcetrapib;   Drug: Placebo;   Drug: Evidence-based medical care for Acute Coronary Syndrome
2 Completed
Has Results
Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease
Condition: Hepatitis C, Chronic
Interventions: Drug: eltrombopag;   Drug: placebo
3 Completed
Has Results
Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Subjects With Hepatitis C Related Liver Disease
Condition: Hepatitis C, Chronic
Interventions: Drug: eltrombopag;   Drug: placebo
4 Completed Phase 3 Trial of Single-Dose Intravesical EOquin® as a Surgical Adjuvant for Noninvasive Bladder Cancer
Condition: Bladder Cancer
Intervention: Drug: EOquin® (Apaziquone)
5 Completed
Has Results
"REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk
Condition: Neoplasms, Prostate
Interventions: Drug: Dutasteride;   Drug: Placebo
6 Completed
Has Results
Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation
Conditions: Atrial Fibrillation;   Atrial Flutter
Interventions: Drug: warfarin;   Drug: apixaban
7 Recruiting The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)
Condition: Myelodysplastic Syndrome
Interventions: Drug: Oral Azacitidine;   Drug: Placebo
8 Completed Warfarin and Antiplatelet Therapy in Chronic Heart Failure
Condition: Heart Failure
Interventions: Drug: Warfarin titrated to an INR of 2.5-3.0;   Drug: Aspirin;   Drug: Clopidogrel 75
9 Completed This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure
Condition: Heart Failure With Reduced Ejection Fraction
Interventions: Drug: LCZ696 200 mg BID;   Drug: Enalapril 10 mg BID
10 Recruiting Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction
Condition: Chronic Heart Failure With Reduced Ejection Fraction.
Intervention: Drug: LCZ696
11 Completed
Has Results
Safety of Inhaled Insulin With Type 1 and Type 2 Diabetes
Conditions: Diabetes, Type 1;   Diabetes, Type 2
Interventions: Drug: Technosphere® Insulin Inhalation Powder;   Drug: Usual Care
12 Completed
Has Results
An Extension to Study MA21573, Evaluating Tocilizumab in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biological DMARDs and/or Anti-tumor Necrosis Factor (TNF) Therapy
Condition: Rheumatoid Arthritis
Intervention: Drug: tocilizumab [RoActemra/Actemra]
13 Completed Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Condition: Ovarian Cancer
Interventions: Drug: MORAb-003 (farletuzumab);   Drug: 0.9% Saline
14 Terminated Phase III Acute Coronary Syndrome
Condition: Acute Coronary Syndrome
Interventions: Drug: Apixaban;   Drug: Placebo
15 Completed A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
Condition: Chronic Hepatitis C Infection
Interventions: Drug: GS-9190;   Drug: GS-9256;   Biological: Pegasys®;   Drug: Copegus®;   Drug: GS-9190 placebo;   Drug: GS-9256 placebo
16 Completed
Has Results
Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children
Condition: Respiratory Syncytial Virus Infections
Interventions: Biological: motavizumab (MEDI-524);   Biological: palivizumab
17 Completed
Has Results
Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
Condition: Attention Deficit Hyperactivity Disorder
Interventions: Drug: Extended-release Guanfacine Hydrochloride;   Drug: Atomoxetine Hydrochloride;   Drug: Placebo Comparator
18 Recruiting A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
Condition: Psoriasis
Intervention: Drug: CP-690,550
19 Active, not recruiting Simtuzumab (GS-6624) in the Prevention of Progression of Liver Fibrosis in Subjects With Primary Sclerosing Cholangitis (PSC)
Condition: Primary Sclerosing Cholangitis (PSC)
Interventions: Biological: Simtuzumab;   Biological: Placebo
20 Terminated Inhaled Technosphere Insulin in Subjects With Diabetes Mellitus and Asthma
Conditions: Diabetes Mellitus, Type 1;   Diabetes Mellitus, Type 2;   Asthma
Intervention: Drug: Technosphere Insulin

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years